Stock NEWBRY NEWBURY PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Market Closed - Nasdaq Stockholm
Other stock markets
 17:00:00 25/06/2024 BST 		5-day change 1st Jan Change
3.4 SEK +6.25% Intraday chart for Newbury Pharmaceuticals AB +3.66% +10.75%
04-10 Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
02-22 Newbury Pharmaceuticals Secures SEK9 Million Sales Order MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
Newbury Pharmaceuticals Secures SEK9 Million Sales Order
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023
Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023
Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023
Newbury, Amarox Sign Distribution Deal for Sweden, Denmark
Newbury Signs Contract with Amarox Limited to Represent and Distribute Their Products in Sweden and Denmark
Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide
Newbury Secures Access to Hospital Product Portfolio in New Partnership
Newbury Pharmaceuticals AB Gains Access to the Nordic Hospital Market with A New Strategic Partnership for Prescription Medicine
Newbury Pharmaceuticals Gets OK to Sell Peptide Product in Sweden
Newbury Pharmaceuticals Announces the Marketing Authorization of Desmopressin Newbury 60, 120 & 240 Mg Sublingual Tablets in Sweden
Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028
Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023
Newbury Pharmaceuticals Announces the Marketing Authorization of Lapatinib Newbury 250 Mg Film-Coated Tablets in Sweden
Newbury Pharmaceuticals' MS Treatment Receives Marketing Authorization in Sweden
Newbury Pharmaceuticals Announces the Marketing Authorization of Dimethyl Fumarate Newbury 120 & 240 Mg Hard Capsule in Sweden
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NEWBRY Stock
  4. News Newbury Pharmaceuticals AB
  5. Other languages